Toth PP, et al. - This post-hoc subanalysis was performed to assess the impact of evolocumab on serum levels and size of lipoprotein particles among hyperlipidemia patients from the DESCARTES trial. Findings demonstrated that evolocumab significantly lowered atherogenic lipoprotein particles including low-density and remnant lipoproteins.